Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cardiol Therapeutics Inc T.CRDL

Alternate Symbol(s):  CRDL | T.CRDL.W.A

Healthcare
Cardiol Therapeutics Inc. (Cardiol) is a Canada-based clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). The Company's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.


TSX:CRDL - Post by User

Cardiol Therapeutics Inc > FDA Approval for Investigational New Drug (IND) Application
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Comment by NewFanCBDon Nov 11, 2020 5:57am
65 Views
Post# 31875920

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:FDA Approval for Investigational New Drug (IND) Application

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:FDA Approval for Investigational New Drug (IND) Application Ridiculously negative. Stop telling lies and innuendos. Your story telling is boorish. You have no idea what is happening. The story here will unfold positively as you will see. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities